Can Maximum Surgical Blood Order Schedule Be Used as a Predictor of Successful Completion of Bloodless Surgery?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Kyung Il | - |
dc.contributor.author | Shin, Jeong Won | - |
dc.date.accessioned | 2021-08-12T01:18:50Z | - |
dc.date.available | 2021-08-12T01:18:50Z | - |
dc.date.issued | 2013-03 | - |
dc.identifier.issn | 2234-3806 | - |
dc.identifier.issn | 2234-3814 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13861 | - |
dc.description.abstract | Background: The Soonchunhyang University Hospital Bloodless Center was established in 2000, and more than 2,000 bloodless surgeries have been performed there since. In this study, the lowest postoperative Hb/preoperative Hb (Hb(low/pre)) ratio and mortality rates of patients who underwent bloodless surgery were analyzed for each maximum surgical blood order schedule (MSBOS) category to assess whether MSBOS can be used as a predictor of successful completion of bloodless surgery. Methods: A total of 971 patients were included. MSBOS was defined as the average number of units of RBCs transfused during each elective surgery. We used the Hb(low/pre) ratio as an alternative to intraoperative blood loss. Frequency of Hb(low/pre) ratios <= 0.5 use of transfusion alternatives, and mortality rates were compared across MSBOS categories. Results: Out of the 971 patients, 701 (72.2%) were categorized as type and screen (T&S), 184 (18.9%) as MSBOS 1, 64 (6.6%) as MSBOS 2, and 22 (2.3%) as MSBOS 4. Transfusion alternatives were used by 397 (40.9%) patients. The frequency of the use of simultaneous erythropoietin and iron, hemostatics, acute normovolemic hemodilution, and Cell Saver (Haemonetics corp., USA) was higher in patients in the higher MSBOS categories. Six (0.6%) patients died within 30 days of surgery. Hb(low/pre) ratios tended to be lower as the level of MSBOS category increased. Conclusions: Surgeries in the higher MSBOS categories tended to be associated with high blood loss and mortality. Active use of transfusion alternatives is recommended in patients in high MSBOS categories who are scheduled to undergo bloodless surgery. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한진단검사의학회 | - |
dc.title | Can Maximum Surgical Blood Order Schedule Be Used as a Predictor of Successful Completion of Bloodless Surgery? | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3343/alm.2013.33.2.116 | - |
dc.identifier.scopusid | 2-s2.0-84876140291 | - |
dc.identifier.wosid | 000316304400005 | - |
dc.identifier.bibliographicCitation | Annals of Laboratory Medicine, v.33, no.2, pp 116 - 120 | - |
dc.citation.title | Annals of Laboratory Medicine | - |
dc.citation.volume | 33 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 116 | - |
dc.citation.endPage | 120 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001746151 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Medical Laboratory Technology | - |
dc.relation.journalWebOfScienceCategory | Medical Laboratory Technology | - |
dc.subject.keywordPlus | TRANSFUSION | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordAuthor | Bloodless surgery | - |
dc.subject.keywordAuthor | MSBOS | - |
dc.subject.keywordAuthor | Hb(low/pre) ratio | - |
dc.subject.keywordAuthor | Mortality | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.